11:57 AM EST, 11/05/2025 (MT Newswires) -- Argenx (ARGX) said Wednesday that Health Canada approved Vyvgart SC as a standalone treatment for adults with active chronic inflammatory demyelinating polyneuropathy, or CIDP.

The authorization was supported by results from the global Adhere study, where 69% of patients showed improvement and the risk of relapse fell 61% versus placebo. Safety findings were consistent with previous studies, the company said.

Vyvgart Sc, administered once weekly via a prefilled syringe, is the first and only Fc receptor blocker approved in Canada for CIDP. It can be self-administered or given by a caregiver, offering greater flexibility for patients, according to the company.

Price: 829.25, Change: -2.23, Percent Change: -0.27